Page 195 - rcv31n3.vp

Revista Uruguaya de Cardiología Actualización en medicamentos antidiabéticos y riesgo cardiovascular
Volumen 31 | nº 3 | Diciembre 2016 María del Pilar Serra Sansone

28. Inzucchi SE, Bergenstal RM, Buse JB, Diamant 38. Hung YC, Lin CC, Wang TY, Chang MP, Sung FC,
M, Ferrannini E, Nauck M, et al. Management of Chen CC. Oral hypoglycaemic agents and the develop-
hyperglycemia in type 2 diabetes, 2015: a patient-cen- ment of non-fatal cardiovascular events in patients
tered approach: update to a position statement of the with type 2 diabetes mellitus. Diabetes Metab Res Rev
American Diabetes Association and the European 2013; 29(8):673-9.
Association for the Study of Diabetes. Diabetes Care
39. Ferrannini E, DeFronzo RA. Impact of glucose-lo-
2015; 38(1):140-9.
wering drugs on cardiovascular disease in type 2 diabe-
29. International Diabetes Federation. Glucose con- tes. Eur Heart J 2015; 36(34):2288-96.
trol therapy: recommendations. En: International Dia-
40. Kao J, Tobis J, McClelland RL, Heaton MR, Da-
betes Federation. Clinical Guidelines Task Force: glo-
vis BR, Holmes DR Jr, et al; Investigators in the
bal guideline for Type 2 diabetes.Brussels: IDF,
Prevention of Restenosis With Tranilast and Its
2012:55-64. Disponible en:http://www. idf.org/sites/de-
Outcomes Trial. Relation of metformin treatment to
fault/files/IDF-Guideline-for-Type-2-Diabetes.pdf.
clinical events in diabetic patients undergoing percuta-
[Consulta: 13 julio 2016].
neous intervention. Am J Cardiol 2004; 93(11):
30. United Kingdom Prospective Diabetes Study 1347-50.
Group. Effect of intensive blood-glucose control with
41. Roussel R, Travert F, Pasquet B, Wilson PW,
metformin on complications in overweight patients
Smith SC Jr, Goto S, et al; Reduction of Athe-
with type 2 diabetes (UKPDS 34). Lancet 1998;
rothrombosis for Continued Health (REACH)
352(9131):854-65.
Registry Investigators. Metformin use and morta-
31. Hong J, Zhang Y, Lai S, Lv A, Su Q, Dong Y, et al; lity among patients with diabetes and atherothrombo-
SPREAD-DIMCAD Investigators. Effects of met- sis. Arch Intern Med 2010; 170(21):1892-9.
formin versus glipizide on cardiovascular outcomes in
42. El Messaoudi S, Nederlof R, Zuurbier CJ, van
patientswithtype2diabetesandcoronaryarterydisea-
Swieten HA, Pickkers P, Noyez L, et al. Effect of
se. Diabetes Care 2013; 36(5):1304-11.
metformin pretreatment on myocardial injury during
32. Boussageon R, Supper I, Bejan-Angoulvant T, coronary artery bypass surgery in patients without dia-
KellouN,CucheratM,BoisselJP, et al. Reapprai- betes (MetCAB): a double-blind, randomised controlled
sal of metformin efficacy in the treatment of type 2 dia- trial. Lancet Diabetes Endocrinol 2015; 3(8):615-23.
betes: a meta-analysis of randomised controlled trials.
43. EppingaRN, HartmanMH, vanVeldhuisenDJ,
PLoS Med 2012; 9(4):e1001204.
Lexis CP,Connelly MA,LipsicE,etal. Effect of
33. Schramm TK, Gislason GH, Vaag A, Rasmussen metformin treatment on lipoprotein subfractions in
JN,Folke F, Hansen ML,etal. Mortality and car- non-diabetic patients with acute myocardial infarction:
diovascular risk associated with different insulin secre- a glycometabolic intervention as adjunct to primary co-
tagogues compared with metformin in type 2 diabetes, ronary intervention in ST elevation myocardial infarc-
with or without a previous myocardial infarction: a na- tion(GIPS-III)trial.PLoSOne2016;11(1):e0145719.
tionwide study. Eur Heart J 2011; 32(15):1900-8.
44. University of Oxford. The Oxford Centre for
34. Evans JM, Ogston SA, Emslie-Smith A, Morris Diabetes, Endocrinology and Metabolism. Diabe-
AD. Risk of mortality and adverse cardiovascular out- tes Trials Unit. Glucose lowering in non diabetic
comes in type 2 diabetes: a comparison of patients trea- hyperglycaemia trial: GLINT. Oxford, UK: University
ted with sulfonylureas and metformin. Diabetologia of Oxford, 2016. Disponible en: https://www.
2006; 49(5):930-6. dtu.ox.ac.uk/GLINT/organisation.php. [Consulta: 10
julio 2016].
35. Johnson JA, Majumdar SR, Simpson SH, Toth
EL. Decreased mortality associated with the use of 45. Katakami N, Yamasaki Y, Hayaishi-Okano R,
metformin compared with sulfonylurea monotherapy Ohtoshi K, Kaneto H, Matsuhisa M, et al. Metfor-
intype2diabetes.DiabetesCare2002;25(12):2244-8. min or gliclazide, rather than glibenclamide, attenuate
progression of carotid intima-media thickness in sub-
36. Roumie CL, Hung AM, Greevy RA, Grijalva CG,
jects with type 2 diabetes. Diabetologia 2004;
LiuX,Murff HJ,etal. Comparative effectiveness of
47(11):1906-13.
sulfonylurea and metformin monotherapy on cardio-
vascular events in type 2 diabetes mellitus: a cohort 46. Meaney E, Vela A, Samaniego V, Meaney A,
study. Ann Intern Med 2012; 157(9):601-10. AsbúnJ,Zempoalteca JC,etal. Metformin, arte-
rial function, intima-media thickness and nitroxida-
37. Jørgensen CH, Gislason GH, Andersson C,
tion in metabolic syndrome: the mefisto study. Clin
Ahlehoff O, Charlot M, Schramm TK, et al.
Exp Pharmacol Physiol 2008; 35(8):895-903.
Effects of oralglucose-lowering drugs onlong termout-
comesinpatientswithdiabetesmellitusfollowingmyo- 47. MatsumotoK,SeraY,Abe Y, Tominaga T, Yeki
cardial infarction not treated with emergent percuta- Y, Miyake S. Metformin attenuates progression of ca-
neous coronary intervention: a retrospective nationwi- rotid arterial wall thickness in patients with type 2 dia-
de cohort study. Cardiovasc Diabetol 2010; 9:54. betes. Diabetes Res Clin Pract 2004; 64(3):225-8.
539